UPDATE: Lilly CEO calls deal an ‘important step’
Eli Lilly and Co.’s planned acquisition of ImClone Systems Inc. is its boldest move yet to replace revenue it will lose once patent coverage for its bestseller Zyprexa expires in three years. The Indianapolis-based drugmaker announced this morning it would pay $6.5 billion in cash to acquire New York-based ImClone, a biotech firm that develops […]